C
카이노스메드
284620KOSDAQ46.5 / 100
Reference Date: 2026-09-08
Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Kainosmed is a biotech company focused on developing innovative therapies for incurable and rare diseases, generating revenue through licensing out drug candidates. The company is currently advancing Parkinson's disease treatments and HIV therapies into Phase 2 clinical trials, while also exploring oncology drug development.
Number of Employees
15people
Average Salary
73.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
7.81Industry Average 1.200.0Point
6.5x industry avg (risky)
ROE
-148.61Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
—Industry Average 100.004.0Point
Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲109.7% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲37.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -109.3% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 1,087Won52-week high 1,08752-week low 1,087
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)2026-08-14
- Neutral반기보고서 (2026.06)2026-08-14